ASTRAZENECA PHARMA INDIA
							
							
								
								
									
										
											| BSE ticker code | 506820 | 
										
											| NSE ticker code | ASTRAZEN | 
										
											| Major activity | Pharmaceuticals | 
										
											| Managing Director | Narayan K. Seshadri | 
										
											| Equity capital | Rs. 5.00 crore; FV Re. 02 | 
										
											| 52 week high/low | Rs. 3375 / Rs. 2437 | 
										
											| CMP | Rs. 3302.00 | 
										
											| Market Capitalisation | Rs. 8255.00 crore | 
										
											| Recommendation | Accumulate at declines | 
									
								 
							 
							Focus on crucial health molecules
							
								Bengaluru-headquartered AstraZeneca Pharma is
								a subsidiary of AstraZeneca Ple UK, a $37,417 billion-insales MNC pharmaceutical giant
								having a portfolio of products for major diseases in areas including oncology,
								cardiovascular, gastro-intestinal, infection, neuroscience, respiratory
								and inflammation. It has been involved in developing the
								Oxford-AstraZeneca Covid-19 vaccine. A BSE-listed company
								which has a workforce of 1,400 across
								the country, it is committed to providing life-changing medicines to patients
								through innovative science and global
								excellence in development and commercialization. The company has an
								innovative portfolio in crucial areas of
								healthcare, including cardiovascular,
								renal and metabolic diseases, oncology and respiratory.
								The company’s Bengaluru manufacturing facility has been rated the finest in Southeast
								Asia with a state-of-theart production facility that meets stringent international
								standards, including WHO-Good Manufacturing Practices (GMP)
								norms. Some of the company’s key brands include Forxiga,
								Brilinta, Imfinzi, Lynparza, Xigaduo Qutern and Zoladex.
							
							
								The company has been going from strength to strength
								on the sales front, with the turnover steadily expanding from
								Rs 594 crore in fiscal 2011 to Rs 806 crore in fiscal 2022.
								However, its performance on the profitability front is disappointing, with its
								operating profit which was Rs 104 crore in
								fiscal 2011 turning negative in fiscal 2013 with a loss of Rs
								68 crore and remaining in the red for the next year. However, subsequently, the company
								has started earning a profit
								which gradually edged up to Rs 135 crore in fiscal 2021
								before declining to Rs 86 crore in fiscal 2022. Its prospects
								going ahead are highly promising.
							
							
								Consider:
							
							
							
								- 
									Going ahead, the company will continue to
									prioritise investments in its focus areas in line with its global
									growth platforms. Accordingly, new products remain a key
									priority and it is committed to maintaining alignment with
									the global pipeline, subject to conduct of clinical trials, regulatory
									approvals and reasonable commercial viability. A
									strong product pipeline in respiratory is expected to drive
									significant growth in the coming years.
								
- 
									The company has joined hands with the
									NASSCOM Centre of Excellence and the partnership has
									led to the discovery of three start- ups.
								
- 
									The growth platform of the company is performing well, with innovative
									molecules like Brilinta, Forxiga,
									Kigduo, Symbicort, Symbicartin and
									Komblgyze. The newer launches of
									innovative molecules like Tagrisso,
									Lynporza and Imitinzi have helped
									it make an impact on the lives of
									patients. Brilinta is approved for
									treatment in acute coronary syndrome and high-risk post-MI patients, and
									continues to register rapid
									growth even after loss of exclusivity.
								
- 
									The company has
									been entering into strategic tie-ups
									to enrich its business portfolio. It is
									on an expansion spree as it is eyeing several deals which
									would be beneficial to it. Recently, it collaborated with Bangalore-based
									Cellworks to jointly work on designing combination therapies to treat drug-
									sensitive and resistant tuberculosis. Farther, the company is engaged in
									signing deals
									with companies like GlaxoSmithKline and Amylin Pharmaceuticals in order to add
									external pieces to their pharmaceutical portions. The company’s partnership
									with Sun Pharma
									Laboratories has helped boost the reach of a crucial drug to
									more patients. This franchise has become the market leader
									by value share in oral anti-platenets, as per Iqvia Health.
								
- 
									The parent company has undertaken a very ambitious plan to more than double its
									new cancer drugs by 2030.
									In order to seek the top slot in the world’s most lucrative
									category of medicines, AstraZeneca has added seven new
									cancer medicines since 2014 after the company’s CEO Pascal
									Sariot warded off a hostile takeover from Pfizer Inc. Now,
									with blockbuster treatments for malignancies in the lungs,
									ovaries and blood, AstraZeneca aspires to be the fastest growing maker of
									cancer drugs. The company has thus the opportunity to be the No 1 oncology
									player. The Indian outfit will
									benefit considerably when the parent company achieves its
									aim by 2030, as the menace of cancer is
									fast growing in India.
								
								The increasing incidence and diagnosis of NCDs, strategic partnerships from
								foreign players with local players, initiatives
								to improve access to healthcare and medicines, a positive outlook of the regulatory
								environment, associated new drug
								launches, implementation of robust digital healthcare initiatives, and expansion
								of the healthcare infrastructure are some
								of the factors that will drive growth in the
								sector in general and in AstraZeneca in
								particular. The key contributors to the
								growth of the company will be rising income levels, greater health awareness,
								increased presence of lifestyle diseases
								and improved access to insurance.
							
							
								PERFORMANCE INDICATORS (Rs. in crore)
							
							
								
									
										
											| Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) | RONW (%) | 
									
									
										
											| 2019-20 | 831.80 | 72.00 | 28.80 | 50.0 | 145.80 | 21.70 | 
										
											| 2020-21 | 813.60 | 91.70 | 36.70 | 100.0 | 182.50 | 22.40 | 
										
											| 2021-22 | 805.60 | 59.51 | 23.80 | 500.0 | 204.60 | 12.30 | 
									
								
							 
						 
						
							
							COCHIN SHIPYARD
							
							
								
								
									
										
											| BSE ticker code | 521064 | 
										
											| NSE ticker code | TRIDENT | 
										
											| Major activity | Other Textile Products | 
										
											| Chairman | Rajinder Gupta | 
										
											| Equity capital | Rs. 509.60 crore; FV Re. 01 | 
										
											| 52 week high/low | Rs. 71 / Rs. 13 | 
										
											| CMP | Rs. 51.75 | 
										
											| Market Capitalisation | Rs. 26371.57 crore | 
										
											| Recommendation | Buy at declines | 
									
								 
							 
							Expanding shipbuilding footprint
							
								The government of India-owned miniratna PSU, Cochin
								Shipyard, is the largest shipbuilding and ship repair facility
								in the country. It is the sole shipyard in the country which is
								managed by the Ministry of Ports. The company has built
								platform supply vessels and double-hulled oil tankers. It is
								also a well-known player on the global ship-building front
								and has by now exported over 45 ships to various commercial clients overseas. The
								company’s
								performance on the financial front is
								also heart-warming. What is more,
								prospects for this mid-cap company
								are quite promising going ahead.
							
							
								Consider:
							
							
							
								- 
									The company has built and
									repaired some of the largest ships in
									India and also the prestigious indigenous aircraft carrier for the Indian
									Navy. Over the years, it has successfully responded to fluctuations in the
									ship-building requirements of the
									market and has evolved from building bulk carriers to smaller
									and more technically sophisticated vessels such as passenger vessels and
									offshore support vessels. The company has
									worked with several leading technology firms in the industry, including Royce
									Marine (Norway), GTT (France) and
									Yard Group (Norway). This has added to its credibility in
									the international markets. Its key ship-building clients in the
									domestic space include the Indian Navy, the Indian Coast
									Guard, DRDO, A&N Administration and the JSW group.
									The company has a robust order book with pending
									orders worth over Rs 10,000 crore and enquiries in addition to benefits it will
									get from ‘Make in India’, ‘Atmanirbhar
									Bharat’ and indigenous defence orders.
								
- 
									The Indian ship-building industry continues to be
									driven by defence requirements. The Indian Navy is planning to increase its
									fleet from the present 137 to 200 by
									2027. This is expected to provide a spurt to the indigenous
									ship-building segment. Besides, the Indian Navy’s
									indigenisation plan is expected to give a fillip to the growth
									of ancillaries and generally improve the ship-building environment in the
									country
								
- 
									As per the AT Kearney report on the ship repair
									industry, though India’s share in global ship repair is less
									than 1%, the country’s location is favourable with 7-9% of
									global trade passing within 300 nautical miles of the coastline. According to
									the report, India has a market potential of
									Rs 2,600 crore from repairs to the domestic fleet, of which
									only a 15% share is currently captured. The report has further highlighted that
									India can
									grow its ship repair industry to Rs
									9,000 crore in the next 10 years
									through infrastructure and process improvement. The report has
									highlighted low levels of process
									efficiency, lack of infrastructure to
									service vessels above 10,000
									DWT and a weak ancillary landscape as road blocks for developing the industry.
									A key recommendation of the report was to lease
									out the repair facilities at major
									ports to specialists to augment revenue opportunities.
								
- 
									In line with the above recommendations, one of
									the major initiatives under the Government of India’s
									‘Sagarmala’ project was to lease out the ship repair facilities
									available at the major ports to specialists to generate more
									revenue and create a positive ship repair industry climate.
									Based on this, CSL was offered the first opportunity for ship
									repair operations and management of the Indira Dock on
									January 18, 2019. CSL has also signed an MoU with Kolkata
									Port Trust to take over their Netaji Subhas Dock on lease.
								
- 
									According to research analysts of ICICI Securities,
									the defence PSU has remained resilient and is seen outperforming the broader
									market. It is performing very well with
									sales turnover during the last 12 years more than doubling
									from Rs 1,462 crore in fiscal 2011 to Rs 3,190 crore in fiscal
									2022, operating profit also more than doubling from Rs
									308 crore to Rs 637 crore during the same 12-year period,
									and the profit at net level shooting up more than two and a
									half times – from Rs 228 crore to Rs 587 crore. The compounded sales growth
									during the last 10 years works out to
									9 per cent and the compounded profit growth around 14
									per cent. The new fiscal year ending March 2023 has started
									on a highly cheerful note, with revenues in Q1 FY2023
									registering a growth of 33.8 per cent yoy to Rs 440.9 crore,
									driven by a 31 per cent
									yoy growth in the shipbuilding segment and a
									47 per cent yoy growth in
									the ship repair segment. EBITDA shot up by 50.6 per cent yoy to
									Rs 31.5 crore as the EBITDA margin
									improved to 7.1 per cent from 6.4 per
									cent in Q1 a year ago. Profit at the net
									level inched up by 47.2 per cent yoy to
									Rs 42.2 crore.
								
- 
									The company has been paying dividends regularly and the rate for
									the last year was Rs 16.75 per share.
									Interestingly, the company has been
									maintaining a healthy dividend payout
									of 35.1 per cent. The company’s stock is
									trading at 1.14 times its book value,
									which is quite attractive.
								
								CONSOLIDATED PERFORMANCE INDICATORS (Rs. in crore)
							
							
								
									
										
											| Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) | RONW (%) | 
									
									
										
											| 2019-20 | 3422.50 | 632.00 | 48.00 | 166.0 | 283.00 | 14.40 | 
										
											| 2020-21 | 2818.90 | 599.20 | 45.50 | 155.0 | 306.60 | 15.50 | 
										
											| 2021-22 | 3190.95 | 565.99 | 43.00 | 168.0 | 334.00 | 13.43 | 
									
								
							 
						 
						
							
							TIME TECHNOPLAST
							
							
								
								
									
										
											| BSE ticker code | 532856 | 
										
											| NSE ticker code | TIMETECHNO | 
										
											| Major activity | Plastic Products Industrial | 
										
											| Managing Director | Sanjay Kulkarni | 
										
											| Equity capital | Rs. 22.61 ; FV Rs. 02 | 
										
											| 52 week high/low | Rs. 126 / Rs. 63 | 
										
											| CMP | Rs. 119.95 | 
										
											| Market Capitalisation | Rs. 2712.63 crore | 
										
											| Recommendation | Buy at declines | 
									
								 
							 
							Polymer solutions for varied clients
							
								Time Technoplast is an Indian multinational conglomerate engaged in the manufacture of
								technology-driven innovative polymer products, with operations in India, Bahrain,
								Egypt, Indonesia, Malaysia, UAE, Taiwan, Thailand, Vietnam,
								Saudi Arabia and the US, and more than 34 production
								facilities across the globe. These products cater to growing
								industry segments like industrial
								packaging solutions, life style products, automotive components,
								healthcare products, infrastructure/
								construction-related products and
								material handling solutions.
							
							
								Promoted by qualified professionals with decades of experience
								– who believe in working hard for
								the company, its customers, its suppliers, its employees and its shareholders — the
								company started as a
								small-scale unit with a production
								facility in Tarapur (Maharashtra) in 1993, and the very next
								year entered into a technological collaboration with the Mauser
								group. Then it started expanding its domestic footprint by
								setting up a plant at Daman (in the Union Territory of Diu and
								Daman) Hosur (Tamil Nadu) and Baddy (Himachal Pradesh).
								Having established itself in all parts of the country, Time
								Technoplast embarked on a strategic expansion overseas in
								the UAE, Bahrain and Thailand in order to serve its customers in the western, southern
								and south eastern regions of
								Asia. Having covered the Asian region, the company made
								inroads in Europe, the US and the Middle East. It also entered into a joint venture
								with the Mauser group to acquire
								to related businesses in other Asian countries. By now, it
								services over 500 institutional clients and its distribution/
								dealer network is spread over 345 cities and towns.
							
							
								The company has been going from strength to strength
								on the financial front, with its consolidated sales turnover
								during the last 12 years expanding from Rs 1,259 crore in
								fiscal 2011 to Rs 3,650 crore in fiscal 2022, with operating
								profit inching up from Rs 236 crore to Rs 506 crore during
								this period. What is more, prospects ahead are all the more
								encouraging.
							
							
								Consider:
							
							
							
								- 
									Time Technoplast does not have many competitors
									globally. Since its inception in 1992, it has set itself apart from
									the competition by focusing on R&D,
									futuristic product design and superior customer service by setting up 28
									manufacturing units and 8 regional
									and marketing offices to meet the demand of Indian and global customers. The
									company focuses on longterm relationships with customers and
									has addressed the varied and expanding requirements of customers
									over a long period. By introducing
									new products, it has obtained additional business from existing customers and
									expanded into new markets.
								
- 
									The company has decided to restructure its overseas business in order to
									capture growth in Asia, the Middle
									East and the US through joint ventures/special purpose vehicles by onboarding
									strategic/investor partners by way of
									sales/transfer/disposal of part of assets/investments of subsidiaries/ material
									subsidiaries/step-down subsidiaries. This
									will enable the company to utilize the process of restructuring for repayment
									of debt, capex for composite cylinders
									(LPG, CNG/hydrogen) and its core business in India to meet
									the huge and expanding market demand. This will ultimately
									benefit its shareholders substantially.
								
- 
									The company has surplus land in Mumbai which it
									wants to dispose of. This, along with its overseas proceeds,
									will go a long way in wiping out its borrowings which amount
									to Rs 906 crore as on March 31, 2022.
								
- 
									Time Technoplast is a regular dividend payer, the
									rate for last year being 150 per cent. The decline in its debt
									will enable the management to step up dividends going ahead.
									The company’s financial position is very strong, with reserves
									at the end of March 2022 standing at Rs
									2,050 crore – almost 90 times its equity
									capital of Rs 23 crore. The company has
									not made any bonus issue so far, and one
									is due now. Discerning investors will do
									well to include this scrip in their portfolio.
									Shares are available around Rs 117.
								
								The future outlook for the company is
								highly positive. Though this is a commodity stock, it is a good buy for long-term
								investors.
							
							
								PERFORMANCE INDICATORS (Rs. in crore)
							
							
								
									
										
											| Year | Net Series | Net Profit | EPS (Rs.) | Div (%) | BV (%) | RONW (%) | 
									
									
										
											| 2019-20 | 3578.00 | 169.10 | 7.50 | 95.0 | 80.00 | 9.70 | 
										
											| 2020-21 | 3004.90 | 103.40 | 4.60 | 70.0 | 83.90 | 5.60 | 
										
											| 2021-22 | 3649.84 | 187.71 | 8.30 | 100.0 | 91.50 | 9.46 |